Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medipal HoldingsMAHLY 82 Return-on-Tangible-Equity is 3.33% as of Mar. 2026, which is 54% below its 10-year median of 7.17. GuruFocus rates MAHLY with a GF Score™ of 82/100 and a GF Value™ of $16.38 (Fairly Valued). The stock has 1 warning sign investors should review. Among 111 Medical Distribution companies, Medipal Holdings ranks worse than 61.26% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Medipal Holdings's annualized net income for the quarter that ended in Mar. 2026 was $129 Mil. Medipal Holdings's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $3,873 Mil. Therefore, Medipal Holdings's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 3.33%.
The historical rank and industry rank for Medipal Holdings's Return-on-Tangible-Equity or its related term are showing as below:
MAHLY'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 4.78 Med: 7.17 Max: 7.81
Current: 7.18
During the past 13 years, Medipal Holdings's highest Return-on-Tangible-Equity was 7.81%. The lowest was 4.78%. And the median was 7.17%.
MAHLY's Return-on-Tangible-Equity is ranked worse than 61.26% of 111
companies
in the Medical Distribution industry
Industry Median: 8.81
vs MAHLY: 7.18
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Medipal Holdings Return-on-Tangible-Equity Related Terms
Medipal Holdings Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Medipal Holdings's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MAHLY vs MCK, CAH, COR: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, Medipal Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medipal Holdings Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Medipal Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Medipal Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 3.33% mean?
Medipal Holdings (MAHLY) has a Return-on-Tangible-Equity of 3.33% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medipal Holdings and its competitors. This is 54% below median its historical median of 7.17. Over the past decade, Medipal Holdings' Return-on-Tangible-Equity has ranged from 4.78 to 7.81. According to the industry distribution chart, Medipal Holdings ranks #68 out of 111 companies in the Medical Distribution industry, placing it in the top 61.3%.
Is Medipal Holdings' Return-on-Tangible-Equity too high?
Medipal Holdings' current Return-on-Tangible-Equity of 3.33% is 54% below median its 10-year median of 7.17. Over the past 10 years, this metric has ranged from a low of 4.78 to a high of 7.81. The Medical Distribution industry median Return-on-Tangible-Equity is 8.81. Medipal Holdings' value of 3.33% is 62.2% below this industry median. Based on the distribution chart, Medipal Holdings ranks #68 out of 111 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Medipal Holdings has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' Return-on-Tangible-Equity compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Medipal Holdings ranks #68 out of 111 companies for Return-on-Tangible-Equity. This places Medipal Holdings in the lower half of its industry. The industry median Return-on-Tangible-Equity is 8.81. Medipal Holdings' value of 3.33% is 62.2% below this benchmark. Historically, Medipal Holdings' own Return-on-Tangible-Equity has ranged from 4.78 to 7.81 over the past decade. While the company's 10-year median is 7.17 vs. the industry median of 8.81, Medipal Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.81, based on 111 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medipal Holdings's current Return-on-Tangible-Equity of 3.33% is 62.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Medipal Holdings and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medipal Holdings's current Return-on-Tangible-Equity is 3.33%, which is 54% below median its own 10-year median of 7.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (MAHLY) is currently considered Fairly Valued. The stock's GF Value™ is $16.38, compared to a current price of $17.99 — trading 9.8% above its estimated fair value. The current Return-on-Tangible-Equity is 3.33%, which is 54% below median its 10-year median of 7.17 and 62.2% below the Medical Distribution industry median of 8.81. Medipal Holdings' overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Medipal Holdings (MAHLY), the current Return-on-Tangible-Equity is 3.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medipal Holdings (MAHLY) Overvalued in 2026?
Based on GuruFocus' analysis, Medipal Holdings stock appears to be overvalued.
The current stock price of $17.99 is trading 9.8% above its estimated GF Value™ of $16.38.
GuruFocus considers Medipal Holdings to be Fairly Valued.
Key valuation signals for MAHLY:
Return-on-Tangible-Equity: 3.33% (54% below median its 10-year median of 7.17)
GF Value™: $16.38 vs. price of $17.99 (9.8% above fair value)
Industry Position: 62.2% below the Medical Distribution median (#68 of 111)
No single metric tells the full story. See the MAHLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
82GF Score
Get the complete analysis for MAHLY
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAHLY has been successfully added to your 
